Xeris Pharmaceuticals, Inc. (XERS)
Stock Price Chart
Key Info
| Market Cap | 125.54M |
| Revenue (ttm) | 4.26M |
| Net Income (ttm) | -129.49M |
| Shares Out | 37.59M |
| EPS (ttm) | -4.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Jul 2, 2020 |
| Last Price | $2.79 |
| Previous Close | $2.73 |
| Change ($) | 0.06 |
| Change (%) | 2.20% |
| Day's Open | 2.91 |
| Day's Range | 2.60 - 3.10 |
| Day's Volume | 13,110,759 |
| 52-Week Range | 1.42 - 12.94 |
More Stats
| Market Cap | 125.54M |
| Enterprise Value | 87.08M |
| Earnings Date (est) | Aug 11, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 37.59M |
| Float | 22.99M |
| EPS (basic) | -4.62 |
| EPS (diluted) | -4.56 |
| FCF / Share | -3.45 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 1.39M |
| Short Ratio | 2.63 |
| Short % of Float | 3.76% |
| Beta | 2.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 29.46 |
| PB Ratio | 7.69 |
| Revenue | 4.26M |
| Operating Income | -125.20M |
| Net Income | -129.49M |
| Free Cash Flow | -113.07M |
| Net Cash | 38.46M |
| Net Cash / Share | 0.85 |
| Gross Margin | 26.26% |
| Operating Margin | -2,937.52% |
| Profit Margin | -3,038.20% |
| FCF Margin | -2,652.98% |
| ROA | -56.41% |
| ROE | -193.02% |
| ROIC | -115.10% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|
| Revenue | 2.72 | 2.42 | 1.56 | 1.08 |
| Revenue Growth | 12.34% | 55.72% | 44.74% | - |
| Gross Profit | 1.12 | 2.42 | 1.55 | 1.07 |
| Operating Income | -122 | -59.34 | -26.63 | -13.23 |
| Net Income | -126 | -60.08 | -26.55 | -13.21 |
| Shares Outstanding | 26.11 | 12.05 | 2.03 | 1.84 |
| Earnings Per Share | -4.81 | -4.99 | -13.09 | -7.17 |
| Operating Cash Flow | -104 | -56.28 | -24.66 | -16.09 |
| Capital Expenditures | -1.11 | -1.51 | -0.70 | -0.04 |
| Free Cash Flow | -105 | -57.79 | -25.36 | -16.12 |
| Cash & Equivalents | 75.55 | 113 | 42.05 | 32.27 |
| Total Debt | 58.31 | 31.89 | - | - |
| Net Cash / Debt | 17.24 | 80.74 | 42.05 | 32.27 |
| Assets | 109 | 120 | 45.00 | 33.53 |
| Liabilities | 94.55 | 44.62 | 4.95 | 2.57 |
| Book Value | 14.44 | 75.41 | -57.83 | -31.93 |
Company Profile
Company Details
| Full Name | Xeris Pharmaceuticals, Inc. |
| Country | United States |
| Employees | 199 |
| CEO | Paul R. Edick |
Stock Information
| Ticker Symbol | XERS |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: XERS |
| IPO Date | June 21, 2018 |
Description
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that is in Phase II clinical trials for the treatment of congenital hyperinsulinism, post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, and hypoglycemia-associated autonomic failure, as well as for treating hypoglycemia associated with intermittent and chronic conditions, and bi-hormonal artificial pancreas closed-loop systems. In addition, it develops continuous subcutaneous glucagon infusion system of ready-to-use glucagon; ready-to-use diazepam formulation, which is in Phase I clinical trial for the treatment of acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is in pre-clinical stage for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.